TRS — TriMas Corporation · 2026-09-04 · Verdict: WATCH · Conviction 2
Price $38.85 (screen row, universe_under2b.csv built 2026-09-04; no live quote available) · Mkt cap $1.39B · EV $712M (adjusted, see §4) · EV/EBIT 13.7x on 2026E adjusted operating profit · FCF yield n/m (H1 2026 adjusted FCF negative $29.0M) · Net cash $681M adjusted ($845.6M as reported) · ADV $15.6M Sources read: 10-K 2026-03-02 (Items 1, 1A, 7), 10-Q 2026-07-31, DEF 14A 2026-03-31, 8-Ks 2026-03-12, 03-18, 04-30, 07-30, Form 4s (12m). No transcript in the bundle.
1. What the business actually does
After the March 16, 2026 sale of TriMas Aerospace, two businesses remain. TriMas Packaging (83% of 2025 continuing sales, $535.5M revenue, $68.1M operating profit) makes polymeric and steel caps, closures, dispensers and pumps under Rieke, Taplast and Rapak, plus a Life Sciences line of test-kit and vascular-delivery components. Specialty Products (17%, $110.2M revenue, $4.2M operating profit) is Norris Cylinder, the last maker of forged Type 1 steel cylinders in the United States (10-K 2025, Item 1). No customer is 10% of consolidated sales, but each segment has one above 10% of its own (Item 1A).
2. Why it is mispriced — the edge case
There is no edge here, and that is the finding. The screen shows 13.3x EV/EBIT with net cash equal to 60% of the market cap, which reads as a cash-rich stub trading for nothing. Both halves are wrong.
The cash is overstated. The pro forma balance sheet filed with the closing 8-K booked a $200.0M current liability for income taxes on the Aerospace gain (8-K 2026-03-18, note (d)), and at June 30, 2026, $164.3M of that was still unpaid in accrued liabilities (10-Q). Reported net cash of $845.6M is therefore closer to $681M of spendable money.
The earnings are overstated more badly. The screen's $41.3M of 2025 EBIT includes a $27.8M net asbestos benefit (a $35.8M insurance recovery asset booked in Q4 2025 against an $8.0M liability true-up) and a $5.4M gain on the Arrow Engine sale (10-K 2025, Item 7). Strip both and 2025 operating profit from continuing operations was roughly $15.5M on $645.7M of sales; management's own measure agrees, at $0.55 of 2025 adjusted diluted EPS (8-K 2026-04-30). Corrected, the multiple is near 13.7x forward adjusted EBIT. About right is not cheap, and nobody is forced to sell: the stock is 13.6% off its high and trades $15.6M a day.
3. Unit economics and growth
Q2 2026 net sales were $174.6M, up 1.6%, but all of that was currency: consolidated organic growth was zero, with Packaging organic sales down 2.1% and Specialty up 10.2% (8-K 2026-07-30, Appendix I). H1 organic growth was 3.4%. Packaging's decline was broad across food and beverage, beauty and home care dispensing and other consumer goods, against life sciences up $3.2M.
Profitability is improving off a low base. Q2 adjusted operating profit rose 29.1% to $14.9M and H1 was $27.6M versus $21.1M, with the Atkins, Arkansas closure done and $10.5M of 2026 savings and $16.0M annualized on track (8-K 2026-07-30). Packaging earned an 11.8% H1 margin; Specialty earned 5.8% and went backwards in Q2 (2.2%, from 4.4%) on raw material lag and labor ramp inefficiency.
Cash conversion is the weak point. H1 2026 adjusted free cash flow was negative $29.0M against positive $8.7M a year earlier, on a $48.7M receivables build and days sales outstanding up 14 days, which management attributes to "increased sales with customers that generally have longer payment terms" (10-Q). That is a pricing-power tell, and not a good one.
4. Balance sheet and capital allocation
Debt is the $400M of 4.125% notes due April 2029 ($396.9M carrying), the revolver is undrawn, credit-agreement leverage is 1.77x on $91.2M of Consolidated Bank EBITDA, and the $1,242.5M of cash earns 3.7% in Treasury money funds (10-Q).
Buybacks are real but the runway is not. TriMas has retired 11,687,751 shares for $359.2M since the initial authorization, 1,996,321 of them for $73.5M in H1 2026, taking the count to 35.9M, down 11.7% year over year (10-Q). Only $76.5M remains authorized, about 5.5% of the cash pile, while management's stated first use of the money is acquisitions in packaging and life sciences through a new Strategic Investment Committee (10-K 2025, Item 1). Director Shawn Sedaghat controls 16.5% via Trend International Holding AG and Swan Family Office (DEF 14A 2026), but other insiders sold a net $877k over twelve months; the only buys were two dividend-sized lots totaling 126 shares (Form 4s).
5. Management: what they said versus what they did
The bench turned over completely: CEO Amato out June 2025, CFO Mell resigned March 2025, a director served as interim CFO, Swart became CFO in December 2025, and the CHRO was terminated in March 2026 (DEF 14A; 8-K 2026-03-12). Snyder's $6.0M of inducement options are premium-priced at $30 through $50, real alignment at $38.85; less good, the 2025 short-term incentive paid at 200% of target. Guidance has been honored: February's $1.50 to $1.70 was reaffirmed in April and the low end lifted in July. One blemish: $53.9M of tax expense was misallocated to continuing operations in Q1 2026 and corrected as an out-of-period adjustment in Q2 (10-Q).
6. Valuation
Adjusted EV is $712M ($1,393.7M cap less $681M of after-tax net cash). Guidance implies FY2026 adjusted operating profit near $52M, from 3% to 6% sales growth with more than 300bp of margin improvement off roughly 4.7% in 2025, so 13.7x. The guide is not a hockey stick: H1 produced $27.6M and H2 needs about $25M, so the 300bp headline is flattered by a weak H2 2025 base.
Bear ($27): organic decline persists, margins stall near 7%, stub worth 9x $47M EBIT plus cash, less value lost on a dilutive deal. Base ($40): $52M adjusted EBIT at 13x, a $676M stub plus $681M cash on 35.5M shares. Bull ($52): cost-out compounds to $62M EBIT by 2027, mix lifts the multiple to 15x, half the cash returns via buyback. Probability-weighted 30/50/20 gives about $39, which is the price.
Reverse DCF: you pay $712M for roughly $39M of NOPAT, so at a 9% cost of capital with capex equal to depreciation the price implies about 3.5% perpetual growth, against Packaging organic sales of negative 2.1% last quarter.
7. Catalysts and timeline
Q3 2026 results in late October (does Packaging organic turn positive, does H2 margin land). Any Strategic Investment Committee announcement. A buyback authorization above the remaining $76.5M. The Aerospace purchase price adjustment, due to settle in 2026.
8. Risks and pre-registered kill criteria
- An acquisition above $300M at more than 10x EBITDA; the cash then belongs to the sellers, not to holders.
- Packaging organic sales negative for two consecutive quarters (Q2 2026 was the first).
- FY2026 adjusted diluted EPS below $1.60, or the repurchase authorization not raised above $76.5M by the Q4 2026 report.
- A Life Sciences goodwill impairment; the 2025 quantitative test cleared by only 9%, and a 1% higher WACC would have triggered a charge (10-K 2025, Item 7).
9. Verdict and one-paragraph summary
WATCH, conviction 2. TriMas screens as a cash box on two errors: the screen counts $164.3M of unpaid Aerospace deal tax as spendable cash, and treats 2025 EBIT of $41.3M as operating earnings when $33M of it was an asbestos insurance recovery and a divestiture gain, leaving real 2025 operating profit near $15.5M. Correct both and you pay about $712M, or 13.7x forward adjusted EBIT, for a low-growth closures maker whose Packaging organic sales fell 2.1% last quarter and whose H1 free cash flow was negative $29M. The operating turn is real, but the buyback that shrank the count 11.7% has only $76.5M of authorization left while management points the remaining $681M at acquisitions. This is worth owning if the cash comes back to shareholders and not if it is spent, and nothing in the filings tells you which, so wait for the Strategic Investment Committee to show its hand.
Research for discussion, not investment advice. Positions and sizing are the reader's decision.